TIDMTRLS
RNS Number : 0763M
Trellus Health PLC
12 September 2023
Trellus Health plc
("Trellus Health" or the "Company")
Appointment of Chief Financial Officer
LONDON, U.K. AND NEW YORK, U.S. (12 September 2023). Trellus
Health plc (AIM: TRLS), which is commercializing a scientifically
validated and clinically proven personalized resilience-driven
self-management solution for chronic health conditions at their
intersection with mental health, announces the appointment of Joy
Bessenger as Chief Financial Officer in a non-Board capacity,
effective from 18 September. Joy's appointment follows the
appointment of Steve Young, Interim Chief Financial Officer, as
full-time CFO of EKF Diagnostics Holdings plc. Joy has been working
as a consultant for Trellus Health since late July as part of an
orderly handover from Steve.
Joy has worked for over 20 years with both privately and
publicly held life sciences and healthcare companies, with
significant experience across finance, operations, corporate
strategy and development, compliance and governance and strategic
communications.
Her most recent full-time role was at IMV, Inc., a
clinical-stage, dual-listed (NASDAQ/TSX) biotechnology company,
where she served as Senior Vice President, Corporate Strategy and
Investor Relations. There, she took responsibility for a large
portion of the CFO role, working closely with the CEO to develop a
new capital markets and corporate strategy, helping to secure a
$25m debt facility and engaging with current and potential
partners, as well as institutional investors.
From 2017-2019, Joy served as Senior Vice President, Finance and
Strategy of IN8bio, a then privately-held biotechnology company,
where she helped raise a $10 million Series A financing, engaging
with new and existing investors. Prior to this, Joy was the
Co-Founder and Chief Financial Officer of 3D Forensic, Inc., a
privately held forensic animation company, where she raised seed
investment from angel investors, and developed a five-year
strategic plan.
Dr. Marla Dubinsky, CEO and Co-Founder of Trellus Health, said:
"I am delighted to welcome Joy to the Trellus Health team as our
new CFO. I believe her wealth of experience in life sciences and
healthcare companies will be of great value to Trellus Health as we
look to further execute our commercial strategy and secure
additional partnerships, having evolved our delivery model and
aligned our expenditure to lengthen the cash runway into at least
2025. On behalf of the Board, I would also like to thank Steve
Young for his contribution to the Company during his time as
Interim CFO, and wish him the best in his new role."
Joy Bessenger, incoming CFO of Trellus Health, said: "I believe
the Trellus Elevate(TM) program has the potential to change the
lives of people with chronic illnesses. I am excited to join
Trellus Health at this stage in its journey and help deliver its
whole-person healthcare approach to as many people as
possible."
For further information please contact:
Trellus Health plc https://trellushealth.com/
Dr. Marla Dubinsky, CEO and Co-Founder Via Walbrook PR
Dr. Daniel Mahony Chairman
Singer Capital Markets (Nominated Tel: +44 (0)20 7496 3000
Adviser and Broker)
Aubrey Powell / Jen Boorer
Walbrook PR Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
Paul McManus / Sam Allen / Mob: +44 (0)7980 541 893 / 0 7748 651 727
Phillip Marriage / 07867 984 082
About Trellus Health plc ( www.trellushealth.com )
Trellus Health (LSE: TRLS) is the first resilience-focused
digital health company targeting the intersection of chronic
illness and mental health. Trellus Health integrates its
proprietary resilience-based methodology with the technology,
tools, and expert coaching and educator team to deliver Trellus
Elevate(TM), a whole-person technology-enhanced experience that
empowers individuals to master their health and results in
relieving disease burden, building self-management skills and
promoting positive health behaviours that improves outcomes and
enables thriving in the face of a chronic condition.
The Company was founded by Mount Sinai faculty members Marla C.
Dubinsky, MD and Laurie Keefer, PhD, both experts at treating and
healing both the physical and emotional impacts of IBD and IBS and
have been innovators for whole person healthcare for a combined 50
years.
The Company was initially focused on inflammatory bowel disease
("IBD"), which includes the chronic incurable conditions of Crohn's
Disease and ulcerative colitis but has now added Irritable Bowel
Syndrome ("IBS"). Given the common emotional and mental health
struggles often experienced by individuals suffering from a variety
of chronic conditions, Trellus Health considers its approach to
have potential utility and demand across many conditions.
The Trellus Elevate(TM) program incorporates the GRITT(TM)
methodology and learnings on resilience from clinical research and
practice conducted at the Mount Sinai IBD Center for more than five
years. This proprietary, resilience-driven methodology has been
scientifically validated to demonstrate meaningful improvements in
patient outcomes, 71% reduction in Emergency Department (A&E)
visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for
significant cost savings for healthcare payers. Patients with IBD
managed with the proprietary resilience methodology also
experienced a 49% reduction in required opioid use and a 73%
reduction in corticosteroid use 12 months following starting the
program which is a major indicator of improved health outcomes(1)
.
Shares in Trellus Health were admitted to trading on AIM in May
2021, under the ticker TRLS. For more information on Trellus
Health, visit: www.trellushealth.com
(1) Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABRGDCRBBDGXB
(END) Dow Jones Newswires
September 12, 2023 02:00 ET (06:00 GMT)
Trellus Health (LSE:TRLS)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Trellus Health (LSE:TRLS)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
